Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Stock Information for Rallybio Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rallybio Corporation

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.